Mean platelet volume in Graves' disease: a sign of hypermetabolism rather than autoimmunity?

Objective: To evaluate the impact of mean platelet volume [MPV] on predicting disease course among patients with Graves1 disease [GD]

Methods: This retrospective study was performed between 2013-2016 at the Outpatient Endocrinology Clinic of Baskent University Faculty of Medicine, Adana hospital on 65 patients with GD. Among participants, 30 cases experienced thyrotoxicosis again during the first six months after discontinuing anti-thyroid drug [ATD] sessions that had been carried out for at least 12 months prior to stopping [Relapse group]. We also observed 35 patients who exhibited normal thyroid functions within six months following ATD withdrawal [Remission group] MPV levels and thyroid function tests were recorded and total duration of ATD therapy was calculated for all participants

Results: The mean MPV level that was measured at the time of drug withdrawal did not differ between groups, being 8.0+/-1.2 microl in the Relapse group vs. 8.0+/-1.0 microL in the Remission group [p=0.81]. However, we found that the relapse MPV was higher than the withdrawal MPV in the Relapse group [9.2+/-1.3 microL] than it was in the Remission group [8.0+/-1.2 microL, p=0.00]

Conclusions: Higher relapse MPV in Relapse group but similar MPV levels in both groups at ATD withdrawal may be attributed to hypermetabolism or hyperthyroidism rather than autoimmunity of GD

Body mass index below obesity threshold implies similar cardiovascular risk among various polycystic ovary syndrome phenotypes

Objective: The aim of this study was to determine the cardiometabolic risk factors in different polycystic ovary syndrome [PCOS] phenotypes

Subjects and Methods: This cross-sectional study was performed between 2010 and 2011. Eighty-nine patients with PCOS and 25 age- and weight-matched healthy controls were included in the study. Patients were grouped using the Rotterdam 2003 criteria as: group 1, oligomenorrhea and/or anovulation [ANOV] and hyperandrogenemia [HA] and/or hyperandrogenism [n = 23]; group 2, ANOV and polycystic ovaries [PCO; n = 22]; group 3, HA and PCO [n = 22]; group 4, ANOV, HA and PCO [n = 22]; group 5, controls [n = 25]. Laboratory blood tests for diagnosis and cardiometabolic risk assessments were performed. Insulin resistance [IR] was calculated in all patients with the homeostasis model assessment of IR [HOMA-IR] formula. An euglycemic hyperinsulinemic clamp test was performed on 5 randomly selected cases in each subgroup, making 25 cases in total, and indicated as the 'M' value [mg/kg/min], which is the total body glucose disposal rate

Results: The mean BMl values of the groups were: group 1, 26.1 +/- 5.3; group 2, 27.9 +/- 5.2; group 3, 24.3 +/- 4.2; group 4, 27.9 +/- 7.5; group 5, 24.7 +/- 5.2 [p > 0.05]. There were no differences in the lipid profile, plasma glucose, HOMA-IR, insulin and M values between the groups [p > 0.05]. Phenotypes with oligomenorrhea/anovulation [groups 1, 2 and 4] were more obese than group 3 [p = 0.039]

Conclusions: The cardiometabolic risk profile was similar among the PCOS subgroups. This finding could be attributed to the mean BMl values, which, being below 30, were not within the obesity range. Obesity appeared to be an important determinant of high cardiovascular risk in PCOS